Tagged with GI

China A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs, a new report by McKinsey that evaluates China’s impact on the global biopharma industry, AstraZeneca’s respiratory plans, and Gilead’s USD…

Global After almost four years leading Sanofi’s second largest market, China, Pius S. Hornstein moves into a global role to focus on the company’s digital transformation. “In the last 8 years, I have been witnessing the incredible opportunities that digital could unlock …” he said in a LinkedIn post announcing the…

Global Pharma companies no longer view digital as a “nice to have” add on, but as an integral part of their business, yet there are still quite a few hurdles to overcome. Insights from pharma industry digital transformation leaders. Industry is on a dedicated and focused journey to leverage data and…

Global Since monkeypox was declared a global emergency by the World Health Organization (WHO) and industrialized countries began stockpiling vaccines, Bavarian Nordic’s shares have more than tripled while Siga Technologies has seen the value of its stock double.   … we are pleased to assist more countries with supply of vaccines…

South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…

India Arshia Bhandari of patient safety thought leadership forum PhVFIT examines how India is embracing a more patient-centric healthcare model via the implementation of a national patient safety implementation framework.   In April 2018, the India Ministry of Health and Family Welfare launched the National Patient Safety Implementation Framework 2018-2025 (NPSIF),…

Global Gilead Sciences’ Jacopo Andreose PhD is a 20+ year pharma veteran and is today responsible for setting company strategy, planning and execution for over 150 countries across Asia, Russia/CIS, Latin and Central America, the Middle East, and Africa. In an exclusive conversation, Andreose outlines how Gilead was able to roll…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

Korea After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge new manufacturing facilities to cope with increased demand, a dedication to carrying out technology transfers at half the speed of…

Turkey After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for its HIV and oncology treatments, announced a USD 60 million investment in Turkey, partnering with local player Pharmactive to produce…

Japan The latest healthcare and pharma news from Japan, including Shionogi’s COVID-19 pill, the Japanese parliament’s green light for emergency approvals of drugs and vaccines and Hitachi’s partnership with Invivoscribe.   Shionogi’s COVID-19 pill  (Reuters) The future of Shionogi & Co Ltd’s experimental treatment, S-217622, is still uncertain. The company recently…

EUCOPE EUCOPE’s Secretary-General Dr. Alexander Natz sees both opportunities and pitfalls with the EU HTA procedure, saying that the next three years will decide the crucial steps and whether the new procedure leads to reduced burdens for developers and faster patient access to innovative therapies.   With the entry into force…